[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-mixed\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-mixed":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,52,81,111,144,176,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100592421","home-based-brain-monitoring-with-a-garment-eeg-to-study-cognitive-decline-in-the-aging-population-100592421",false,"NCT06993207","HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population","Validation of a Home-use Instrument for the Quantification of Cognitive Function in a Population at Risk of Dementia","Hogar","General Inclusion Criteria:\n\n* Native Spanish speaker.\n* Agree to the examination procedures and tests.\n* Ability to involve a close family member or friend for functional evaluation.\n* Normal or corrected-to-normal color vision.\n* No medical condition requiring chronic systemic medication with psychoactive effects causing confusion.\n* No severe psychiatric (according to DSM-V) or neurological diseases (epilepsy with frequent seizures (\\>1\u002Fmonth) in the last year, multiple sclerosis, etc.).\n* No diseases that may interfere with cognitive functions (renal insufficiency on hemodialysis, liver cirrhosis, chronic pulmonary disease with oxygen therapy, solid organ transplant, fibromyalgia, active cancer under treatment).\n* No severe hearing and\u002For visual impairments, neurodevelopmental, or psychomotor disorders.\n* No brain injuries that may interfere with cognitive functions (history of traumatic brain injury with parenchymal injury or macroscopic ischemic stroke of large extra-axial vessels or hemorrhagic stroke, brain surgery, brain tumors, or other causes that could result in acquired brain damage such as brain chemotherapy or radiotherapy).\n* No treatment with antipsychotic agents in the 6 months prior to the initial assessment.\n* No medical condition requiring chronic systemic medication with psychoactive effects causing confusion. No psychiatric or neurological medication.\n* No alcohol or drug abuse.\n* No serious health problems in the last 12 months (especially neurological or cardiac disorders).\n\nInclusion Criteria 'Mild Dementia' group:\n\n* Diagnosis of Alzheimer's type dementia, based on a clinical and cognitive assessment conducted by a physician.\n* Diagnosis of vascular or mixed type dementia, based on a clinical and cognitive assessment conducted by a physician.\n* Lack of autonomy in: 1. basic activities according to the Barthel Index; 2. instrumental activities according to the Lawton Index. Both indices assess dependence associated with the diagnosis of dementia, distinguishing it from the diagnosis of mild cognitive impairment.\n\nInclusion Criteria 'Mild Cognitive Impairment' group:\n\n* Diagnosis of mild cognitive impairment, based on a clinical and cognitive assessment conducted by a physician.\n* Preserved autonomy in: 1. basic activities according to the Barthel Index; 2. instrumental activities according to the Lawton Index. Both indices assess dependence associated with the diagnosis of dementia, distinguishing it from the diagnosis of mild cognitive impairment\n\nInclusion Criteria 'Subjective Cognitive Decline' group:\n\n* Adherence to SCD-I criteria.\n* Attendance at primary care consultation with memory complaints lasting more than 6 months.\n* Absence of a diagnosis of mild cognitive impairment or dementia.\n* Onset of subjective cognitive decline in the last 5 years.\n* Concerns related to subjective cognitive decline (not associated with an acute event) expressed by the participant and\u002For an informant.\n* Cognitive performance within the normal range on cognitive tests (MMSE (Mini Mental State Exam) \\\u003C 26 \u002F MIS (Memory Impairment Screen) \\\u003C 6).\n* No severe depressive symptoms, indicated by scores \\> 17\\* on the 30-item Geriatric Depression Scale.\n\nInclusion criteria No impairment group:\n\n* Cognitive performance within the normal range on cognitive tests (MMSE \\\u003C 26 \u002F MIS \\\u003C 6).\n* Absence of a diagnosis of mild cognitive impairment or dementia.\n* Not meeting the criteria for SCD-I \\[21\\].\n* Independent person living in their own home.\n* No subjective memory complaints.",true,"ALL","60 Years",{"count":21,"type":22},500,"ESTIMATED","3 Years","OBSERVATIONAL","This study will investigate the validity of the HOGAR EEG\u002FPSG monitoring kit designed by Bitbrain as a tool for characterizing and assessing cognitive function in older adults, as well as for detecting and predicting cognitive decline. The kit consists of two EEG headbands and a mobile computing device that allows measurements of sleep patterns (PSG) and brain activity (EEG) in a home environment.",[27,28,29,30,31,32],"Dementia","Mild Cognitive Impairment","Dementia Alzheimers","Dementia, Mixed","Subjective Cognitive Decline","Dementia, Vascular",[27,34,35,36,37,38],"MCI","Memory","cognitive decline","EEG","Sleep EEG","RECRUITING","2025-05-19",{"date":42,"type":43},"2025-05-28","ACTUAL",{"date":45,"type":43},"2024-01-15",{"date":47,"type":22},"2028-12-31",{"name":49,"class":50},"Bitbrain","INDUSTRY",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":63,"studyType":24,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100528706","dementia-risk-registry-for-young-and-middle-aged-csvd-patients-in-the-next-10-years-100528706","NCT06164262","Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years","Dementia Risk rEgistry for Young And Middle-aged CSVD Patients in the Next 10 Years（DREAM-10）","DREAM-10","Inclusion Criteria:\n\n1. Patients with any of the CSVD-related MRI imaging markers, including recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and superficial cortical siderosis.\n2. Patients aged from 30 to 60 years.\n3. Sign informed consent.\n\nExclusion Criteria:\n\n1. Unable to cooperate with inspectors.\n2. Known dementia.\n3. Other cognitive diseases (such as Alzheimer's disease, Parkinson's disease, or thyroid disease).\n4. Serious systemic illness, such as heart, liver, kidney disease or major mental illness.\n5. Contraindications for imaging examination.\n\nExit Criteria:\n\n1. Not meet the inclusion criteria.\n2. For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator.\n3. Any adverse or serious adverse events during the study period judged by investigator.","30 Years",{"count":62,"type":22},1000,"10 Years","Age-related cerebral small-vessel disease (CSVD) is a major cause of dementia, predominantly affecting individuals over 60 years of age, with a prevalence exceeding 70% in the elderly population. However, the correlation between the burden of CSVD and the progression of cognitive impairment in young and middle-aged individuals remains uncertain. DREAM-10 is an observational, prospective study that enrolled individuals aged 30-60 years, who were free from known dementia but exhibited imaging markers related to CSVD. Through prospective registration and follow-up, this study will collect data on patients with CSVD, including clinical information, neuropsychological assessments, multimodal Magnetic Resonance Images (MRI) and retinopathy characterized by Optical Coherence Tomography Angiography (OCTA). CSVD related features seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, brain atrophy, cortical superficial siderosis. Utilizing this data, the researchers aim to investigate the potential dementia risk among young and middle-aged individuals with CSVD over the forthcoming decade, along with identifying its predictive factors.",[66,30,67,68],"Cerebral Small Vessel Diseases","Health Behavior","Health Behavior, Risky",[66,27,70],"Cardiovascular health","2025-05-18",{"date":73,"type":43},"2025-05-21",{"date":75,"type":43},"2024-01-01",{"date":77,"type":22},"2034-12-01",{"name":79,"class":80},"Zhejiang Provincial People's Hospital","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":51},"100516897","white-matter-hyperintensity-shape-and-glymphatics-100516897","NCT06010511","WHIte MAtter Hyperintensity Shape and Glymphatics","White Matter Hyperintensity Shape and Glymphatics","WHIMAS","Inclusion Criteria:\n\n* Admitted to the memory or the geriatric clinic of the LUMC, the Alrijne Hospital Leiden or the Haga Hospital the Hague\n* From 65 years of age\n* Eligible for MRI\n* Native-level Dutch speaker\n\nExclusion Criteria:\n\n* Claustrophobia\n* Contraindications for MRI such as metal implants and pacemaker\n* Use of benzodiazepines\n* Initiated treatment with antidepressants less than 6 weeks prior to inclusion\n* Not being able to provide written informed consent (assessed by the treating physician)\n* Individuals that have been declared mentally incapacitated\n* Other severe neurological disease besides dementia related\n* Cognitive impairment due to known other neurological disease\n* Previous brain surgery","65 Years",{"count":91,"type":22},50,"In a society with increased life expectancy, the economic, social and personal burden of dementia increases. Dementia is often caused by a combination of neurovascular and neurodegenerative diseases. Impaired brain clearance is suggested to be closely related to dementia development, as waste products (e.g. amyloid beta) accumulate in the brain, leading to neurodegeneration. Cerebral small vessel disease (SVD) is the most common neurovascular disease that even contributes to about 45% of dementia pathophysiology in patients with a diagnosis of Alzheimer's dementia. White matter hyperintensities of presumed vascular origin (WMH) are the key brain MRI manifestation of cerebral SVD. There is evidence that the currently known and MRI-visible WMH are landmarks of an already progressed stage of the underlying pathology. The pathophysiology of WMH has been attributed to multiple underlying mechanisms, such as hypoperfusion, defective cerebrovascular reactivity and blood-brain barrier dysfunction. Furthermore, different anatomical locations and different types of WMH are related to different underlying pathological changes. Using ultra-high field 7T MR imaging techniques WMH lesions can be detected with a higher sensitivity and resolution than on 3T MRI. The hypothesis is that different pathological mechanisms of cerebral SVD lead to variations in WMH shape. Moreover, the brain clearance ('glymphatic') system of the brain appears to be tightly connected to dementia pathology. Thus, novel markers of glymphatic activity could aid to describe and understand the pathology.",[66,30,32,28,94,95],"Cognitive Impairment","Cognitive Decline",[97,98,99,100,36,101],"dementia","cerebral small vessel disease","White matter hyperintensities","cognitive impairment","Glymphatics","2025-04-10",{"date":104,"type":43},"2025-04-13",{"date":106,"type":43},"2023-01-18",{"date":108,"type":22},"2027-08-31",{"name":110,"class":80},"Leiden University Medical Center",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":18,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100507909","uppsala-dalarna-dementia-and-gait-project-100507909","NCT05893524","Uppsala-Dalarna Dementia and Gait Project","UDDGait™","Inclusion Criteria:\n\n* Patients undergoing memory assessment at at Uppsala University Hospital, Sweden\n* Patients undergoing memory assessment at at Falu Hospital, Sweden\n* Cognitively unimpaired individuals with a Mini Mental State Examination (MMSE) score of \\> 26\n\nExclusion Criteria:\n\n* Inability to walk three meters back and forth\n* Inability to rise from a sitting position\n* Indoor use of a walking aid\n* Current or recent hospitalization (within the last 2 weeks)\n* Need of an interpreter to communicate in Swedish","37 Years","94 Years",{"count":121,"type":22},550,"UDDGait™ is a multidisciplinary research project with the overreaching goal of providing an aid for early identification of cognitive impairment and risk of dementia development, thereby providing a basis for adequate symptom relieving and health promoting interventions.\n\nA new concept is investigated for this purpose: a \"dual-task-test\", which implies the combination of a well-established mobility test (Timed Up-and-Go, TUG) with a simultaneous verbal task (i.e. TUG dual-task, TUGdt). This type of test has been judged as a potential aid for early identification of dementia disease. More research is needed to further examine the test's validity, reliability and predictive capacity.\n\nThe overall aim is to investigate if TUGdt is useful as an aid for prediction of dementia disease. To ensure the results, the aim is also to evaluate the test's measurement properties and to generate normative reference values of healthy control persons.",[27,30,124,125,28,126],"Dementia Senile","Dementia of Alzheimer Type","Subjective Cognitive Impairment",[128,129,130,27,28,126,131,132,133],"Timed Up-and-Go, TUG","TUG dual-task","Cognitive tests","Alzheimer's disease","Step parameters","Video recorded tests","2025-02-11",{"date":136,"type":43},"2025-02-12",{"date":138,"type":43},"2015-04-09",{"date":140,"type":22},"2026-12-24",{"name":142,"class":80},"Dalarna University",2,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":18,"minAge":89,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":155,"phases":156,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":51},"100512614","multidimensional-rehabilitation-programs-for-cognitive-impairment-in-comorbid-outpatients-a-randomized-controlled-trial-100512614","NCT05954741","Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial","Comparing the Effectiveness of Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial","RCTCogRehab","Inclusion Criteria:\n\n* Age Between 65 and 80 years.\n* Neurocognitive Disorder due to vascular disease with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset \\\u003C 12 months.\n* Neurocognitive Disorder due to multiple etiology with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset \\\u003C 12 months.\n\nExclusion Criteria:\n\n* Other known neurological conditions involving cognitive functioning (e.g. Parkinson's disease, Multiple Sclerosis, head trauma, alcohol abuse).\n* Severe organic instability.\n* Neoplasia in progress.\n* Severe psychiatric condition.\n* Illiteracy.\n* Severe perception deficits.\n* Severe motor disability.\n* Specific intellectual deficit.\n* Participation in other forms of training or neurostimulation in the previous 6 months.\n* Pharmacological interventions of neurological pertinence in the month before the study.","80 Years",{"count":154,"type":22},75,"INTERVENTIONAL",[157],"NA","Dementias secondary to cerebrovascular diseases are of significant epidemiological and clinical relevance. As a result, the management of individuals with comorbid dementia should involve early diagnosis, effective treatment, and patient-centered care planning, both in specialist and in non-specialist settings. It is well known that physical exercise can improve various aspects of health, including resistance, balance, strength, and cognitive functions such as attention and executive performance. However, the efficacy of cognitive rehabilitation is still not definitive and requires further clarification. Preliminary evidence suggests that a combination of cognitive and motor training along with novel technological approaches has the potential to maintain or improve compromised cognitive function more effectively compared to a single intervention. A multidomain intervention could enhance cognitive functioning in elderly individuals with multiple morbidities. In the present study, patients with early neurocognitive impairment based on a vascular disorder or due to multiple etiologies, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, will be screened in an outpatient multidisciplinary setting and subsequently undergo different models of rehabilitation training.\n\nPrimary aim of this study:\n\n\\- Assess the effectiveness of different rehabilitation protocols for improving cognitive functions in patients with comorbid cognitive impairment. Specifically, the investigators will test the effectiveness of three rehabilitation protocols (digital-based cognitive rehabilitation combined with motor rehabilitation, paper-based cognitive rehabilitation combined with motor rehabilitation, and motor rehabilitation alone) by means of a set of multidimensional outcome measures.\n\nSecondary aims:\n\n\\- evaluating the enhancement of cognitive performance using various cognitive questionnaires categorized by cognitive domains. Additionally, the investigators will examine multidimensional variables such as motor skills, mood and anxiety levels, quality of life, patient adherence to treatment, the role of communication in patient management, caregiver burden, and the usability of digital devices (when utilized).",[94,27,160,161,30],"Comorbidities and Coexisting Conditions","Vascular Dementia",[27,163,164,165,166],"Comorbidity","Cognitive rehabilitation","Motor rehabilitation","Digital-based cognitive rehabilitation","2024-10-01",{"date":169,"type":43},"2024-10-03",{"date":171,"type":43},"2024-02-29",{"date":173,"type":22},"2026-01",{"name":175,"class":80},"Istituti Clinici Scientifici Maugeri SpA",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":155,"phases":187,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":51},"100555590","phase-2-cannabidiols-role-in-dementia-management-100555590","NCT06514066","Cannabidiol's Role in Dementia Management","Cannabidiol's Role in Dementia Management: Evaluating Cognitive, Quality of Life, and Well-being Outcomes in Malaysia","MyC4D","Inclusion Criteria:\n\n1. Age: Participants (male and female) must be 50 years of age or older at the time of enrollment. This criterion is necessary to ensure that participants can legally provide informed consent for their participation.\n2. Diagnosis: Participants must have a confirmed diagnosis of mild to severe dementia based on DSM-5 and Clinical Dementia Rating (CDR). Diagnosis should be confirmed by either neurologist, psychiatrist or geriatrician that attend the pattients.\n3. Stability of Condition: Participants' disease status must be stable at the time of enrollment, as determined by the investigator. For example, seizure frequency for those with epilepsy should be consistent for a specified period (e.g., the past three months) before study entry.\n4. Consent: The caregivers of the participants must provide written informed consent to participate in the study. The consent form must be read, understood, and signed by the caregivers before any study-specific procedures are performed.\n5. Ability to Comply: Participants' caregivers must be willing and able to comply with all study procedures and requirements needed by the study. The caregivers must ensure that the participants has the ability to ingest oral medication, and they need to complete surveys on behalf of the participants on their phone, record log seizures (if applicable), and bring the patients to attend all necessary study visits.\n6. Health Status: Participants must be in a health state, as determined by the investigator that will not put them at undue risk of harm from participating in the study or interfere with the study's ability to achieve its objectives.\n7. Additional Criteria for Cancer Patients: Cancer patients must not be on any active chemotherapy and radiation treatment, as determined by the investigator.\n\nThe exact specifications of these criteria will be determined in consultation with Malaysian clinical experts and will be clearly defined in the study's protocol. These criteria are intended to ensure the study's results are valid, reliable, and applicable to the target population.\n\nExclusion Criteria:\n\n1. Cannot fulfil all the requirement as above.\n2. Substance Use: Active usage of substances\u002Fmedications such as cocaine, opiates, benzodiazepines, barbiturates, amphetamines, morphine, methadone, methamphetamines, oxycodone, phencyclidine, tricyclic antidepressants, tetrahydrocannabinol, buprenorphine, methylenedioxymethamphetamine, propoxyphene.\n3. Concurrent Treatments: Participants currently participating in another clinical trial or using other experimental treatments for their condition. Participants who have used any medication, dietary supplements (and\u002For grapefruit juice), or combination of medications and supplements known to alter the metabolism of, or interact with CBD (bupropion, rifampin, barbiturates, phenothiazines, cimetidine, etc.) 14 days prior to and during the duration of the study.\n4. Significant Health Risks: Participants with significant cardiovascular, hepatic, renal, respiratory, or psychiatric disease, which, in the investigator's opinion, would place the participant at undue risk or interfere with the results of the study. History of impaired renal function or elevated liver enzymes at prescreening. The exclusionary lab values are: 3x nl AST\u002FALT, 1.5x bilirubin or eGFR less than 30 ml\u002Fmin. Having present or past medical conditions, including a DSM-5 Axis I psychiatric disorder, history of cardiac disease, arrhythmias, neurological disease of central origin, head trauma, and seizures.\n5. Hypersensitivity: Individuals with known hypersensitivity to CBD or any component of the study formulation.","50 Years",{"count":186,"type":22},486,[188,189],"PHASE2","PHASE3","This trial investigates the therapeutic benefits of cannabidiol (CBD) for Dementia patients in Malaysia. As dementia becomes increasingly prevalent worldwide, there's a pressing demand for impactful remedies. This research will delve into CBD's influence on cognitive functions, daily activities, mental health, and overall life quality of dementia sufferers. Utilizing a range of established assessment instruments, including the ADAS-COG subscale for cognitive effects, the NPI score for psychological well-being, and the QOLAD questionnaire for life quality, we aim to discern CBD's potential in ameliorating the conditions of those with dementia. This study's results could shape novel treatment methods and improved care for dementia patients, benefiting not just Malaysia but the world at large.",[32,30],"NOT_YET_RECRUITING","2024-07-17",{"date":195,"type":43},"2024-07-23",{"date":197,"type":22},"2024-09-01",{"date":199,"type":22},"2025-10-01",{"name":201,"class":80},"Hospital Pengajar Universiti Putra Malaysia",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":17,"sex":18,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":51},"100441071","pumch-dementia-longitudinal-cohort-study-100441071","NCT05023564","PUMCH Dementia Longitudinal Cohort Study","Peking Union Medical College Hospital (PUMCH) Dementia Longitudinal Cohort Study","Inclusion Criteria:\n\n* Neurodegenerative dementia diagnosis based on 2011 NIA-AA criteria of Dementia\n* Fixed care giver and can follow up regularly\n\nExclusion Criteria:\n\n* Not demented, including MCI\n* Systemic severe diseases and severe vision or hearing problem effecting follow up and neuropsychological evaluation\n* Without fixed care giver\n* Reject informed consent\n* Expected life shorter than 2 years","18 Years",{"count":211,"type":22},20000,"The PUMCH Dementia Cohort is a hospital-based, observational study of Chinese elderly with cognitive impairment.",[27,32,214,30,29,215,216],"Dementia With Lewy Bodies","Dementia Frontal","Dementia, Mild","2022-09-10",{"date":219,"type":43},"2022-09-13",{"date":221,"type":43},"2020-12-01",{"date":223,"type":22},"2040-12-31",{"name":225,"class":80},"Peking Union Medical College Hospital"]